


IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on October 25, 2006.

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. SPO-127
Serial No. 10/578,015

David R. Saliwanchik
David R. Saliwanchik, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : *Not yet assigned*
Applicants : Hiroshi Tsuboi, Shuji Ikegami, Tomonori Kamiyama, Zai-si Ji, Yukio Asami,
Hiroyuki Itou, Munehiro Oda, Kazuo Shin
Serial No. : 10/578,015
Filed : May 3, 2006
Conf. No. : *Not yet assigned*
For : Plant-Derived Beta3-Adrenergic Receptor Agonist Substances and Uses
Thereof

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371.

Please note that references Kadowaki *et al.* (R3), Saito *et al.* (R8), and Yoshida *et al.* (R12) are not in English; however, attached are their English translations.


Copies of references F1 through F15, and R1, R2, R4, R6, R9, and R10 are not provided since they were cited in the International Search Report, and as such, should have been provided directly by the WIPO under the exchange program between the USPTO, the EPO and the JPO. Furthermore, F1 through F15 and R2, R4, and R6 were also cited in the Written Opinion.

Please note that a copy of pending Application No. 10/577,612 is also attached. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

In accordance with 37 CFR §1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

DRS/wrc

Attachment: Form PTO/SB/08 (3 pages)
Copy of International Search Report
Copies of cited references (8)



PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

Substitute for form PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/578,015
Filing Date	May 3, 2006
First Named Inventor	Hiroshi Tsuboi
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	SPO-127

Sheet

1

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-10/577,612 (Pending US App.)	04-28-2006 (date filed)	Tsuboi <i>et al.</i>	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	F1	JP	2-163067	A	06-22-1990	Nakajima, K.	All	
	F2	JP	5-236910	A	09-17-1993	Mizuno, T. <i>et al.</i>	All	
	F3	JP	7-61927	A	03-07-1995	Okuda, T. <i>et al.</i>	All	
	F4	JP	8-198769	A	08-06-1996	Nishimura, K. <i>et al.</i>	All	
	F5	JP	9-143070	A	06-03-1997	Uchino, K. <i>et al.</i>	All	
	F6	JP	9-176010	A	07-08-1997	Morino, M. <i>et al.</i>	All	
	F7	JP	10-95732	A	04-14-1998	Uchino, K. <i>et al.</i>	All	
	F8	JP	2000-344673	A	12-12-2000	Hazama, K. <i>et al.</i>	All	
	F9	JP	2001-233768	A	08-28-2001	Wenzel, U. <i>et al.</i>	All	
	F10	JP	2002-80362	A	03-19-2002	Murase, T. <i>et al.</i>	All	
	F11	JP	2002-524480	A	08-06-2002	Bok, SH, <i>et al.</i>	All	
	F12	JP	2003-113100	A	04-18-2003	Mitani, M. <i>et al.</i>	All	
	F13	JP	2003-128571	A	05-08-2003	Ono, H. <i>et al.</i>	All	
	F14	JP	2004-141163	A	05-20-2004	Inafuku, M. <i>et al.</i>	All	
	F15	JP	2004-307365	A	11-04-2004	Mori, S. <i>et al.</i>	All	
	F16							
	F17							
	F18							

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/578,015	
			Filing Date	May 3, 2006	
			First Named Inventor	Hiroshi Tsuboi	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Sheet	2	of	3	Attorney Docket Number	SPO-127

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	DE SOUZA <i>et al.</i> , "Beta ₃ -Adrenoceptor Agonists as Anti-diabetic and Anti-obesit Drugs in Humans," <i>Curr. Pharm. Des.</i> , September 2001, pp. 1433-1449, Vol. 7, No. 14.	
	R2	ISHIKAWA <i>et al.</i> , "Effect of Flavonoids on the Differentiation of 3T3-L1 Adipocytes," <i>Food Sci. Technol. Res.</i> , 2001, pp. 154-160, Vol. 7, No. 2.	
	R3	KADOWAKI, T., "Progress in research on adipocyte & obesity," <i>Jikken Igaku</i> , October 1996, pp. 2206-2208, Vol. 14, No. 16.	x
	R4	KUPPUSAMY <i>et al.</i> , "Potentiation of β -Adrenoceptor Agonist-Mediated Lipolysis by Quercetin and Fisetin in Isolated Rat Adipocytes," <i>Biochemical Pharmacology</i> , 1994, pp. 521-529, Vol. 47, No. 3.	
	R5	NAGASE <i>et al.</i> , "Expression of Uncoupling Protein in Skeletal Muscle and White Fat of Obese Mice Treated with Thermogenic β_3 -Adrenergic Agonist," <i>J. Clin. Invest.</i> , June 1996, pp. 2898-2904, Vol. 97, No. 12.	
	R6	NURALIEV <i>et al.</i> , "The Efficacy of Quercetin in Alloxan Diabetes," <i>Enksperimental 'naya Klin Farmakol</i> , 1992, pp. 42-44, Vol. 55, No. 1.	
	R7	REVUELTA <i>et al.</i> , "Involvement of cAMP and β -adrenoceptors in the relaxing effect elicited by flavonoids on rat uterine smooth muscle," <i>Journal of Autonomic Pharmacology</i> , 1999, pp. 353-358, Vol. 19.	
	R8	SAITO <i>et al.</i> , "Uncoupling protein and β_3 -adrenergic receptor in brown adipocyte," <i>Jikken Igaku</i> , October 1996, pp. 2222-2227, Vol. 14, No. 16.	x
	R9	WASSEL <i>et al.</i> , "Flavonoids of Nelumbo nucifera Gaertn and Biological Evaluation," <i>Egypt. J. Pharm. Sci.</i> , 1996, pp. 585-596, Vol. 37, No. 1-6.	
	R10	WEYER <i>et al.</i> , "Development of β_3 -Adrenoceptor Agonists as Antiobesity and Antidiabetes Drugs in Humans: Current Status and Future Prospects," <i>Drug Development Research</i> , 2000, pp. 80-93, Vo. 51.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/578,015
				Filing Date	May 3, 2006
				First Named Inventor	Hiroshi Tsuboi
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	3	of	3	Attorney Docket Number	SPO-127

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R11	YOSHIDA <i>et al.</i> , "Anti-Obesity and Anti-Diabetic Effects of CL 316,243, A Highly Specific β_3 -Adrenoceptor Agonist, in Yellow KK Mice," <i>Life Sciences</i> , 1994, pp. 491-498, Vol. 54, No. 7.	
	R12	YOSHIDA <i>et al.</i> , "Significance of β_3 -adrenergic receptor gene polymorphism on obesity and obesity-related SNPs," <i>Igaku no Ayumi</i> , January 29, 2000, pp. 555-560, Vol. 192, No. 5.	x
	R13	YUGARANI <i>et al.</i> , "Effects of Polyphenolic Natural Products on the Lipid Profiles of Rats Fed High Fat Diets," <i>Lipids</i> , 1992, pp. 181-186, Vol. 27, No. 3.	
	R14		
	R15		
	R16		
	R17		
	R18		
	R19		
	R20		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.